Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

Antiretroviral therapy during the earliest stage of acute HIV infection (Fiebig I) might
minimize establishment of a latent HIV reservoir and thereby facilitate viremic control after …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

Highly potent and broadly neutralizing anti-HIV-1 antibodies (bNAbs) have been used to
prevent and treat lentivirus infections in humanized mice, macaques, and humans,,,,,,,,,,,. In …

Despite considerable global investment, only 60% of people who live with HIV currently
receive antiretroviral therapy. The sustainability of current programmes remains unknown …

Elicitation of broadly neutralizing antibodies (bnAbs) is a primary HIV vaccine goal. Native-
like trimers mimicking virion-associated spikes present nearly all bnAb epitopes and are …

Prophylactic vaccination of rhesus macaques with rhesus cytomegalovirus (RhCMV) vectors
expressing simian immunodeficiency virus (SIV) antigens (RhCMV/SIV) elicits immune …

Long-term delivery of anti-HIV monoclonal antibodies (mAbs) using adeno-associated virus
(AAV) vectors holds promise for the prevention and treatment of HIV infection. We describe a …

Antibodies have a long history in antiviral therapy, but until recently, they have not been
actively pursued for HIV‐1 due to modest potency and breadth of early human monoclonal …